A Study to Compare Tenofovir Disoproxil Fumarate Versus Adefovir Dipivoxil for the Treatment of HBeAg-Positive Chronic Hepatitis B

ClinicalTrials.gov ID: NCT00116805

Public ClinicalTrials.gov record NCT00116805. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced Oct 29, 2026, 11:22 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Randomized, Double-Blind, Controlled Evaluation of Tenofovir DF Versus Adefovir Dipivoxil for the Treatment of HBeAg Positive Chronic Hepatitis B

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

The primary objectives of this study are to compare the efficacy, safety, and tolerability of tenofovir disoproxil fumarate (TDF) versus adefovir dipivoxil (ADV) for the treatment of HBeAg-positive chronic hepatitis B. Participants will receive TDF or ADV for 48 weeks (double-blind). After 48 weeks, eligible participants switched to open-label TDF for up to 480 weeks.

Study identification

NCT ID: NCT00116805
Recruitment status: Completed
Study type: Interventional
Phase: Phase 3
Lead sponsor: Gilead Sciences; Industry
Enrollment: 266 participants

Conditions and interventions

Conditions

Chronic Hepatitis B

Interventions

TDF Drug
ADV Drug
TDF placebo Drug
ADV placebo Drug
FTC/TDF Drug

Drug

Eligibility (public fields only)

Age range: 18 Years to 69 Years
Sex: All
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: Jun 2005 (Actual)
Primary completion: May 2007 (Actual)
Completion: Jan 2016 (Actual)
Last update posted: Mar 9, 2017

2005 – 2016

United States locations

U.S. sites: 20
U.S. states: 10
U.S. cities: 17

Facility	City	State	ZIP	Site status
Not listed	Orange	California	92868	—
Not listed	Pasadena	California	91105	—
Not listed	San Diego	California	92105	—
Not listed	San Jose	California	95116	—
Not listed	Miami	Florida	33136	—
Not listed	Atlanta	Georgia	30308	—
Not listed	Atlanta	Georgia	30309	—
Not listed	Honolulu	Hawaii	96817	—
Not listed	Baltimore	Maryland	21229	—
Not listed	Ann Arbor	Michigan	48109	—
Not listed	Detroit	Michigan	48202	—
Not listed	St Louis	Missouri	63104	—
Not listed	Flushing	New York	11355	—
Not listed	New York	New York	10021	—
Not listed	New York	New York	10029	—
Not listed	New York	New York	10032	—
Not listed	Fairfax	Virginia	22031	—
Not listed	Falls Church	Virginia	22042	—
Not listed	Richmond	Virginia	23298	—
Not listed	Seattle	Washington	98101	—

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 67 non-U.S. sites.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT00116805, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted Mar 9, 2017 · Synced Oct 29, 2026

Open the official record

The complete public registry record, listed eligibility criteria, and available contact information for NCT00116805 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →